background
possibl
role
human
coronaviru
hcov
lower
respiratori
tract
diseas
lrtd
hematopoiet
cell
transplant
hct
recipi
patient
hematolog
malign
hm
well
studi
method
conduct
retrospect
review
hcthm
patient
hcov
detect
bronchoalveolar
lavag
bal
hcov
strain
identifi
bal
sampl
use
strainspecif
polymeras
chain
reaction
mortal
rate
compar
among
hct
recipi
lrtd
caus
hcov
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
piv
multivari
cox
regress
analysi
result
identifi
patient
episod
hcov
lrtd
among
avail
bal
sampl
strain
overal
patient
requir
oxygen
therapi
diagnosi
die
within
day
diagnosi
respiratori
copathogen
detect
episod
includ
virus
n
fungi
n
bacteria
n
mortal
rate
differ
patient
without
copathogen
p
multivari
model
mortal
associ
hcov
lrtd
similar
seen
rsv
influenza
piv
lrtd
hct
recipi
adjust
hazard
ratio
confid
interv
p
vs
rsv
adjust
cell
sourc
cytopenia
copathogen
oxygen
use
steroid
use
conclus
hcov
lrtd
patient
hct
hm
associ
high
rate
oxygen
use
mortal
mortal
associ
hcov
lrtd
hct
recipi
appear
similar
seen
rsv
influenza
viru
piv
respiratori
virus
caus
lower
respiratori
tract
diseas
lrtd
immunocompromis
host
associ
signific
morbid
mortal
develop
widespread
use
new
molecular
diagnost
techniqu
clinic
impact
previous
underdiagnos
respiratori
virus
popul
remain
uncertain
particularli
true
human
coronaviru
hcov
addit
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronavirus
strain
hcov
acknowledg
human
pathogen
previou
studi
demonstr
hcov
second
common
viru
identifi
upper
respiratori
tract
hematopoiet
cell
transplant
hct
recipi
case
fatal
pneumonia
relat
hcov
without
copathogen
also
report
mainli
hct
popul
two
previou
studi
describ
possibl
role
hcov
lrtd
howev
studi
includ
limit
number
hct
recipi
patient
hematolog
malign
hm
outcom
analys
could
done
purpos
studi
describ
clinic
characterist
outcom
hct
recipi
patient
hm
hcov
detect
lower
respiratori
tract
base
test
bronchoalveolar
lavag
bal
fluid
mortal
rate
compar
among
hct
recipi
lrtd
caus
hcov
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
piv
identifi
hct
recipi
patient
hm
hcov
detect
clinic
bal
sampl
patient
fred
hutchinson
cancer
research
center
univers
washington
seattl
children
hospit
may
februari
identifi
addit
hct
recipi
hcov
detect
bal
sampl
previous
report
cohort
demograph
clinic
data
collect
abovement
institut
databas
medic
chart
review
also
compar
hct
recipi
hcov
lrtd
previous
report
cohort
hct
recipi
lrtd
caus
rsv
influenza
viru
piv
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
reversetranscript
polymeras
chain
reaction
rtpcr
perform
hcov
bal
sampl
serum
specimen
lung
biopsi
autopsi
sampl
accord
previous
publish
protocol
viral
load
hcov
determin
quantit
rtpcr
use
bal
sampl
hcov
identifi
bal
specimen
use
consensu
hcov
assay
part
multiplex
pcr
use
detect
respiratori
virus
strainspecif
pcr
perform
use
save
bal
sampl
describ
previous
perform
rtpcr
detect
hcov
rna
frozen
serum
sampl
drawn
day
day
bal
adequ
lung
tissu
avail
curl
cut
fresh
frozen
tissu
formalinfix
paraffinembed
ffpe
tissu
block
rtpcr
ffpe
sampl
frozen
sampl
extract
use
rnaeasi
ffpe
kit
rnaeasi
mini
kit
respect
qiagen
hilden
germani
sampl
underw
fragment
size
analysi
qualiti
rtpcr
target
amplicon
housekeep
gene
size
rang
base
pair
bp
hcov
lrtd
defin
hcov
detect
bal
sampl
patient
sign
lrtd
eg
cough
dyspnea
new
pulmonari
infiltr
bal
specimen
underw
broad
diagnost
test
includ
convent
cultur
bacteria
fungi
mycobacteria
virus
shell
vial
cultur
cytomegaloviru
immunofluoresc
antibodi
stain
pneumocysti
jirovecii
legionella
fungal
pcr
aspergillu
galactomannan
enzymelink
immunosorb
assay
cytopatholog
examin
hcov
consid
sole
respiratori
pathogen
abovement
microbiolog
test
result
bal
specimen
neg
pulmonari
bacteri
coinfect
defin
bacteri
load
colonyform
unit
per
millilit
bal
specimen
compat
radiolog
find
clinic
cours
viru
fungu
detect
bal
sampl
consid
respiratori
copathogen
highest
steroid
dose
week
prior
hcov
lrtd
cell
count
immedi
prior
hcov
lrtd
record
oxygenfre
day
ventilatorfre
day
defin
day
aliv
free
oxygen
support
mechan
ventil
respect
respiratori
death
defin
death
occur
consequ
respiratori
failur
morpholog
rereview
avail
bal
sampl
lung
biopsi
autopsi
lung
tissu
perform
hematoxylin
eosinstain
section
boardcertifi
pathologist
expertis
transplant
patholog
patient
outcom
compar
use
fisher
exact
test
categor
variabl
wilcoxon
ranksum
test
continu
variabl
appropri
summari
variou
patient
cohort
accord
analysi
type
shown
supplementari
figur
first
episod
hcov
lrtd
per
subject
use
outcom
analys
also
exclud
hct
recipi
histori
lung
transplant
outcom
analys
except
evalu
risk
factor
mortal
follow
hcov
lrtd
univari
cox
proport
hazard
model
use
evalu
risk
factor
overal
mortal
day
diagnosi
hcov
lrtd
variabl
p
valu
univari
model
candid
multivari
model
multivari
cox
regress
model
adjust
respiratori
virus
hcov
rsv
influenza
piv
cell
sourc
neutrophil
count
lymphocyt
count
monocyt
count
presenc
copathogen
steroid
dosag
oxygen
use
diagnosi
perform
patient
respiratori
viral
copathogen
exclud
analysi
probabl
overal
mortal
hct
recipi
day
follow
diagnosi
lrtd
estim
use
kaplanmei
method
logrank
test
use
compar
mortal
curv
among
subgroup
twosid
p
valu
consid
statist
signific
statist
analys
perform
use
sa
softwar
version
window
sa
institut
inc
cari
north
carolina
identifi
total
patient
episod
hcov
detect
rtpcr
bal
sampl
tabl
show
characterist
hct
recipi
patient
hm
two
patient
develop
hcov
lrtd
twice
two
hct
recipi
histori
lung
transplant
underw
lung
transplant
bronchiol
obliteran
relat
previou
hct
receiv
lung
transplant
cystic
fibrosi
hct
pediatr
patient
male
identifi
cohort
median
time
hcov
lrtd
hct
recipi
day
rang
day
patient
develop
hcov
lrtd
day
day
follow
transplant
respect
patient
hcov
lrtd
day
follow
transplant
receiv
either
immunosuppress
therapi
chemotherapi
control
underli
disord
eg
relaps
hematolog
malign
graftvshost
diseas
prior
diagnosi
lrtd
twentythre
recipi
transplant
may
respiratori
viral
pcr
panel
test
becam
routin
median
time
hcov
lrtd
hct
patient
day
rang
day
similar
entir
cohort
time
bal
acut
respiratori
symptom
new
pulmonari
infiltr
present
major
episod
tabl
among
avail
frozen
bal
sampl
identifi
major
episod
occur
winter
spring
regardless
strain
type
figur
respiratori
pathogen
detect
bal
sampl
episod
includ
virus
episod
fungi
episod
bacteria
episod
figur
two
respiratori
copathogen
detect
approxim
half
episod
two
patient
respiratori
copathogen
well
concomit
bacteremiafungemia
patient
found
staphylococcu
aureu
blood
bal
clostridium
nonperfringen
candida
glabrata
blood
respiratori
copathogen
found
episod
episod
strain
p
median
viral
load
hcov
bal
sampl
differ
among
strain
figur
hcov
rna
detect
serum
sampl
prior
follow
hcov
lrtd
avail
episod
five
lung
biopsi
sampl
lung
abbrevi
hcov
human
coronaviru
lrtd
lower
respiratori
tract
diseas
pbsc
peripher
blood
stem
cell
bronchiol
obliteran
n
lung
transplant
bronchiol
obliteran
n
lung
transplant
cystic
fibrosi
n
radiat
pneumonia
n
asthma
n
prolong
acut
respiratori
distress
syndrom
n
diffus
alveolar
hemorrhag
n
cystic
fibrosi
n
autopsi
sampl
test
rtpcr
among
patient
ffpe
sampl
fresh
frozen
sampl
obtain
within
day
lrtd
diagnosi
qualiti
control
fragment
size
analysi
rtpcr
rna
sampl
show
ffpe
specimen
could
reliabl
amplifi
bp
frozen
specimen
reliabl
amplifi
bp
sampl
lung
tissu
posit
hcov
rtpcr
obtain
day
bal
patient
outcom
summar
exclud
patient
second
episod
hcov
lrtd
histori
lung
transplant
tabl
outcom
day
lrtd
diagnosi
compar
hct
recipi
patient
hm
hct
recipi
like
fewer
oxygen
ventilatorfre
day
patient
hm
outcom
day
hcov
diagnosi
also
compar
patient
without
respiratori
copathogen
statist
differ
found
twentyeight
patient
sampl
avail
patholog
review
includ
bal
sampl
lung
biopsi
sampl
autopsi
lung
specimen
patient
without
respiratori
copathogen
either
nonspecif
find
multinucl
giant
cell
nuclear
enlarg
supplementari
figur
lung
tissu
patient
posit
hcov
rtpcr
morpholog
featur
note
lung
biopsi
inflam
tissu
lymphocyt
neutrophil
cytolog
atypia
supplementari
figur
total
hct
recipi
singl
respira
influenza
viru
piv
among
hct
recipi
without
respiratori
viral
copathogen
without
copathogen
differ
p
p
respect
figur
furthermor
differ
seen
cohort
stratifi
without
oxygen
requir
time
lrtd
diagnosi
p
figur
univari
cox
regress
model
use
evalu
risk
factor
overal
mortal
hct
recipi
lrtd
caus
hcov
rsv
influenza
viru
piv
without
respiratori
viral
copathogen
tabl
multivari
model
cell
sourc
bone
marrow
respiratori
bacteri
fungal
copathogen
low
neutrophil
count
low
monocyt
count
steroid
use
oxygen
requir
diagnosi
associ
overal
mortal
tabl
studi
demonstr
presenc
hcov
bal
sampl
immunocompromis
host
significantli
associ
high
rate
respiratori
support
mortal
hct
recipi
appear
affect
patient
hm
although
respiratori
copathogen
frequent
detect
clinic
outcom
patient
similar
without
copathogen
mortal
rate
hct
recipi
day
develop
hcov
lrtd
similar
rate
seen
establish
respiratori
pathogen
includ
rsv
influenza
viru
piv
figur
tabl
hcov
strain
identifi
bal
sampl
regardless
presenc
copathogen
least
hcov
strain
present
nearli
half
year
sar
mer
recogn
highli
humanpathogen
coronavirus
caus
acut
sever
frequent
fatal
lrtd
although
strain
hcov
also
human
pathogen
clinic
impact
hcov
lrtd
remain
unclear
especi
immunocompromis
patient
previou
prospect
studi
weekli
nasal
surveil
sampl
first
day
hct
demonstr
prolong
hcov
shed
upper
respiratori
tract
week
half
subject
includ
asymptomat
patient
addit
respiratori
copathogen
identifi
half
episod
studi
given
prolong
asymptomat
shed
frequent
detect
respiratori
copathogen
attribut
poor
clinic
outcom
hcov
lower
respiratori
tract
may
difficult
current
studi
followup
bal
procedur
perform
assess
prolong
shed
lower
respiratori
tract
howev
prior
studi
includ
patient
cancer
demonstr
case
hcov
detect
followup
bal
specimen
argu
asymptomat
prolong
shed
lower
respiratori
tract
data
need
defin
shed
durat
immunocompromis
popul
studi
clinic
outcom
includ
intens
respiratori
support
day
aliv
without
hospit
mortal
significantli
differ
patient
without
copathogen
suggest
hcov
lower
respiratori
tract
contribut
sever
lrtd
regardless
copathogen
lung
tissu
patient
posit
hcov
rtpcr
patient
subsequ
develop
prolong
oxygen
requir
also
support
potenti
pathogen
hcov
demonstr
clinic
signific
hcov
lrtd
hct
recipi
compar
mortal
rate
hct
recipi
hcov
lrtd
respiratori
virus
use
data
present
mean
standard
deviat
unless
otherwis
indic
multivari
cox
regress
analysi
found
mortal
rate
hcov
lrtd
compar
seen
rsv
influenza
viru
piv
given
common
percept
hcov
rel
benign
pathogen
base
limit
data
data
somewhat
surpris
advers
impact
oxygen
requir
time
diagnosi
subsequ
clinic
outcom
suggest
substanti
acut
lung
injuri
occur
clinic
outcom
potenti
affect
inflamm
rather
viru
therefor
mortal
rate
day
follow
lrtd
caus
hcov
rsv
influenza
viru
piv
also
compar
accord
oxygen
requir
time
lrtd
diagnosi
statist
signific
differ
found
data
combin
suggest
hcov
lrtd
significantli
associ
poor
clinic
outcom
immunocompromis
popul
previou
studi
mainli
immunocompet
host
demonstr
distinct
associ
particular
hcov
strain
upper
respiratori
tract
sampl
diseas
sever
lrtd
although
case
report
strain
identifi
lower
respiratori
tract
sole
pathogen
hct
recipi
systemat
data
limit
first
studi
describ
hcov
strain
detect
bal
sampl
without
respiratori
copathogen
larg
immunocompromis
popul
howev
instanc
strain
limit
abil
examin
specif
hcov
strain
associ
increas
diseas
sever
lrtd
studi
larger
sampl
size
help
character
role
particular
hcov
strain
studi
show
rel
late
present
hcov
lrtd
follow
transplant
median
time
hcov
lrtd
follow
hct
day
longer
median
day
lrtd
caus
rsv
day
piv
day
influenza
day
may
part
due
fact
cohort
includ
patient
transplant
prior
introduct
routin
hcov
pcr
test
separ
analyz
patient
underw
transplant
introduct
respiratori
viral
pcr
panel
determin
median
time
diagnosi
remain
similar
day
major
patient
develop
hcov
lrtd
day
follow
transplant
receiv
either
chemotherapi
immunosuppress
therapi
predispos
factor
explain
rel
lower
incid
hcov
lrtd
earli
transplant
differ
infect
control
practic
earli
transplant
factor
affect
progress
lrtd
earli
vs
late
transplant
may
play
role
studi
need
determin
hcov
often
caus
lrtd
late
transplant
studi
evalu
largest
cohort
hcov
lrtd
confirm
bal
patient
hct
hm
hcov
strainspecif
quantit
pcr
bal
sampl
addit
rtpcr
perform
serum
specimen
lung
biopsi
sampl
autopsi
sampl
main
limit
studi
rel
small
sampl
size
prevent
us
detect
small
differ
perform
multivari
analys
evalu
risk
factor
mortal
patient
hcov
lrtd
anoth
limit
fact
bal
sampl
avail
twothird
patient
strain
identif
limit
abil
compar
clinic
virolog
differ
among
hcov
strain
among
total
lung
biopsi
autopsi
sampl
lung
biopsi
sampl
taken
day
bal
posit
hcov
rtpcr
lower
rate
detect
may
due
fact
neg
sampl
obtain
day
day
diagnosi
lrtd
suggest
time
collect
sampl
may
late
identifi
hcov
lung
specimen
furthermor
sampl
optim
preserv
rtpcr
thu
sensit
hcov
may
suboptim
demonstr
high
rate
respiratori
support
includ
oxygen
use
mechan
ventil
requir
well
high
mortal
immunocompromis
patient
hcov
identifi
lower
respiratori
tract
mortal
rate
associ
hcov
lrtd
transplant
recipi
similar
seen
respiratori
viral
pathogen
includ
rsv
influenza
viru
piv
thu
conclud
hcov
appear
signific
respiratori
pathogen
popul
studi
import
observ
hcov
highli
preval
immunocompromis
host
appreci
hcov
import
lower
respiratori
tract
pathogen
could
impact
clinic
manag
includ
risk
stratif
futur
studi
provid
rational
develop
antivir
therapi
studi
need
clarifi
particular
hcov
strain
viral
load
correl
clinic
outcom
identifi
risk
factor
progress
lrtd
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
